SCHEMBL3274446

SCHEMBL3274446

O=C(O)CNC(=O)c1ccc(S(=O)(=O)N(Oc2ccc(F)cc2)c2cccc(F)c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP5 P45974 4/20 0.47
RAB9A P51151 2/20 0.46
ALDH1A1 P00352 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA9 Q16790 1/20 0.46
IDO1 P14902 1/20 0.43
MAPT P10636 2/20 0.42
ATM Q13315 1/20 0.42
SLC6A9 P48067 2/20 0.42
SLC6A5 Q9Y345 2/20 0.42
TAS2R14 Q9NYV8 1/20 0.39
BCL2L1 Q07817 1/20 0.39
MCL1 Q07820 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.39
MCHR1 Q99705 1/20 0.39
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3054532 0.93 USP5 (0.45) USP5RAB9AALDH1A1CA1CA2
SCHEMBL3273830 0.92 RAB9A (0.49) USP5RAB9AALDH1A1CA1CA2
SCHEMBL3275033 0.88 RAB9A (0.46) RAB9AALDH1A1MAPTSMN1; SMN2NPC1
SCHEMBL15104078 0.85 NPC1 (0.46) USP5RAB9AALDH1A1SMN1; SMN2NPC1
SCHEMBL3281465 0.85 NPC1 (0.46) USP5RAB9AALDH1A1SMN1; SMN2NPC1
SCHEMBL3049479 0.85 TAS2R14 (0.50) ALDH1A1TAS2R14
SCHEMBL3047858 0.84 CA1 (0.54) USP5RAB9AALDH1A1CA1CA2
SCHEMBL15103824 0.84 THRA (0.47) RAB9AMAPTSMN1; SMN2NPC1KDM4E
Hydrochloric Acid SCHEMBL3274980 0.83 ALDH1A1 (0.41) USP5RAB9AALDH1A1SLC6A9SLC6A5
SCHEMBL15103826 0.83 USP5 (0.42) USP5RAB9AALDH1A1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2076491-B1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-07-17 EP disclosed
US-8481527-B2 Benzamide derivatives as bradykinin antagonists RICHTER GEDEON NYRT. (HU) 2013-07-09 US disclosed
US-20100087423-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-04-08 US disclosed
EP-2076491-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS Richter Gedeon NYRT (HU) 2009-07-08 EP disclosed
WO-2008068540-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087423-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS BDKRB1, BDKRB2, HRH1 USP5 2347/4885RAB9A 2075/4885ALDH1A1 2842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.